文章引用说明 更多>> (返回到该文章)

BOEHRINGER MANNHEIM GMBH (1973) Phenoxyalkylcarbonsaured-erivate and verfahrenzur herstellung der- selben. DE, 2149070.

被以下文章引用:

  • 标题: 贝特类调血脂药物的研究进展The New Idea in the Synthesis of Lipid-Regulator Fibrates

    作者: 夏莹, 额尔敦, 乌恩

    关键字: 高血脂, 贝特类, 合成进展, 活性评价Hyperlipidemia, Fibrates, Synthesis Progress, Activity Evaluation

    期刊名称: 《Hans Journal of Medicinal Chemistry》, Vol.2 No.4, 2014-11-18

    摘要: 贝特类药物在调血脂领域具有举足轻重的位置,它在降低甘油三酯,高密度脂蛋白,总胆固醇方面具有显著疗效,与临床上应用较多的他汀类药物相比,贝特类药物的不良反应较轻。本综述在对高脂血症和调血脂药物进行介绍的基础上,主要阐述了贝特类调血脂药物的作用机制,说明其优势,对近5年国内外贝特类药物的合成方向及药理活性进行综述,包括全合成的路线优化,结构改造制备双受体激动剂,改善油水分配系数,贝特类药物与具有调血脂活性的天然产物结合等,以期为贝特类的进一步研究提供方向。The lipid-regulating agent fibrate plays an important role in lowering the blood lipid. It can signif-icantly reduce the level of total cholesterol, triglyceride and high-density lipoprotein in blood, and it has less side-effect than the mostly used Statins. In this review, we mainly show the mechanism and advantages of the fibrates, as well as the introduction of the disease high-blood-lipid or the li-pid-regulating agents. We summary the synthesis and pharmacological activities in the past 5 years at home and abroad, including the better routes of its synthesis, changing the construction to get the double-receptor agonist, improving the oil-water partition coefficient and the binding rate in vivo. So we can get the new idea for the further study.

在线客服:
对外合作:
联系方式:400-6379-560
投诉建议:feedback@hanspub.org
客服号

人工客服,优惠资讯,稿件咨询
公众号

科技前沿与学术知识分享